Miami Clinical Research ’s Post

Top 5 Challenges of Managing Clinical Trials As a practice in the life sciences industry, clinical trials are essential for developing new drugs and treatment methods. https://lnkd.in/d87WMMYZ

Excited to share my latest article on clinical trial supply management! 📈🥼 Clinical trials are becoming more challenging in line with the increased complexity of investigational drugs that focus on personalized medicine, smaller patient populations and rarer indications. In this article, I dive into the 4 top trends influencing this space, and how to de-risk your supply chain. Read the full article here 👉 https://lnkd.in/e2VQcQqB #clinicaltrials #drugdevelopment  

If you remove money from research and development and conduct fewer clinical trials, you’ll be left with fewer drug approvals and new treatments. It’s a simple equation. This piece explains more: https://lnkd.in/ejWwNxsi

FDORA calls for greater diversity of patients in research. What do you see as the root causes preventing diverse populations currently and how can we reduce these? I think about how often I go to the doctor (which is not enough), but I would be much more inclined to complete a telehealth call and save a few hours in the commute time alone. We need this same thought process in clinical trials using modern technology and practices to go direct to the patients. If we can do this, we can start to attract a wider population.

📢 NEW Blog | Real-World Evidence in Clinical Drug Development In our latest article, our specialists discuss Real-World Data (RWD) and how it's optimising clinical trials by providing insights beyond controlled settings. Click the link below to read the full article where we delve into the benefits, challenges, and regulatory perspectives of incorporating Real-World Evidence (RWE) into drug development, highlighting its impact on patient outcomes and the future of healthcare. Read the full article here: https://hubs.ly/Q02JRvT90 #ClinicalTrials #DrugDevelopment #RealWorldEvidence #HealthcareInnovation #Quanticate

Excellent article written by Heather Granato on #clinicaltrials, specifically the influence of #pharma clinical research design on #nutra trials. Along with other experts in the clinical #research space, Joshua Baisley weighs in with some key drivers behind FDA's guidance and what we still need to consider in the nutra industry including potential impact on study planning, costs, and operations. Explore these and more: https://lnkd.in/guKeJ5EZ

The Food and Drug Omnibus Reform Act (FDORA) will work to ensure accurate representation in clinical trials. But how can pharmaceutical companies achieve this standard if it is not already a priority?    Jennifer Byrne, Irfan Khan, MD and Marie Rosenfeld say technology could help find an answer.     As Byrne says, “I strongly believe this new space will enable us to work more effectively with the immense quantity of data available through health systems and use AI optimizations to reach those known patient populations. We start with such a wide funnel; this empowers us to get it down to where we can predict those known patients. I think AI can help us address the ethical, moral, and public health responsibility we must reach these patients with. Our inability to do so thus far is at the heart of the problem today.”    Hear more insights from these industry leaders below: https://lnkd.in/e6nfTa7c #clinicaltrials #patientengagement #patientsupport #patientcentricity #patientfocused

Medical research is progressing rapidly to keep up with the increase in complex diseases and new treatment options. This has highlighted the need for innovation in clinical trials to facilitate enhanced communication and collaboration between various stakeholders (clinicians, researchers, patients, etc.). By way of open dialogue and communication, this can accelerate the development of novel therapies in order to improve patient outcomes in complex diseases while also providing means to efficiently exchange insight. Read more about the Center for Clinical Trial Innovation to know more about how the US FDA is working towards enhancing communication and collaboration & overall innovation in the space of clinical trials! https://lnkd.in/gQfyyaSh Meet us at BIO and DIA to discuss your requirements for clinical trials! 🤝 Meet us at BIO International: https://lnkd.in/gJt7Vxwv 🤝 Meet us at DIA Global: https://lnkd.in/grrwWGU6 #BIO2024 #DIA2024 #pharma #clinical #trial #innovation #regulatoryservices #USFDA #medical #research

In the latest collaboration from ACRO and TransCelerate BioPharma Inc., Nicole Stansbury of Premier Research and Madeleine Whitehead of Roche discuss the impact that ICH E6(R3) will have on Good Clinical Practice and implications for innovation. Read the feature in pharmaphorum: https://bit.ly/3UIQAvm

Real-world diversity demonstrates how different patients respond to treatments. Without this representation, trial efficacy can fall short. Join experts from Biogen, Tufts Center for the Study of Drug Development, ICON plc, and Cognivia on December 4 for a webinar exploring Diversity Action Plan strategies—from improving patient recruitment and retention to reducing data variability. In the webinar, you will learn: ✅ The importance of a coherent and comprehensive diversity action plan-integrated approach ✅ Valuable insights from regulatory, industry and academic leaders ✅ How to mitigate the data variability impact on clinical trial data interpretation when implementing a diversity action plan Register today: https://lnkd.in/eAmrbDAF